Your Article Summary
Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases
Cancer, 07/01/09
Kao J et al. - Addition of SU (25 to 37.5 mg) to IGRT is tolerable in patients with oligometastases, without potentiation of RT toxicity. On the basis of promising antitumor responses observed with this novel combination, a multi-institutional phase 2 trial using SU 37.5 mg/RT 50 Gy is ongoing.
Related Articles
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 89%
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09
Relevance Score: 88%
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09
Relevance Score: 87%
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09
Relevance Score: 87%
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-2a compared with sunitinib
British Journal of Cancer, 11/20/09
Relevance Score: 84%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
Journal of Clinical Oncology, 12/10/09
18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation
European Journal of Cancer, 12/10/09
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumour types
European Journal of Cancer, 12/10/09

See Latest Articles